PortfoliosLab logoPortfoliosLab logo
TATYY vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TATYY vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tate & Lyle PLC ADR (TATYY) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TATYY achieves a 50.19% return, which is significantly higher than AZN's -5.80% return. Over the past 10 years, TATYY has underperformed AZN with an annualized return of 2.55%, while AZN has yielded a comparatively higher 12.78% annualized return.


TATYY

1D
0.00%
1M
0.21%
6M
44.68%
YTD
50.19%
1Y
7.76%
3Y*
-4.75%
5Y*
-0.40%
10Y*
2.55%
ALL TIME*
3.83%

AZN

1D
-0.99%
1M
-13.07%
6M
-6.66%
YTD
-5.80%
1Y
17.91%
3Y*
8.37%
5Y*
10.71%
10Y*
12.78%
ALL TIME*
12.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$431.89M$497.68M$403.88M
$6.37K$16.58K$46.42K

TATYY vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
TATYY
Tate & Lyle PLC ADR
50.19%-35.21%-0.61%-0.36%18.05%-0.65%-1.93%19.27%-4.33%9.74%
AZN
AstraZeneca PLC
-5.80%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between TATYY and AZN is 0.09, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.09

Correlation (3Y)
Balances recent behavior with more history.

0.11

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.11

Correlation (10Y)
Provides a long-term view across more market conditions.

0.10

Correlation (All Time)
Calculated using the full available price history since Jan 4, 2016

0.11

Fundamentals

Market Cap

TATYY:

$7.03B

AZN:

$131.47B

EPS

TATYY:

£2.15

AZN:

$13.34

PE Ratio

TATYY:

10.23

AZN:

12.71

PS Ratio

TATYY:

0.70

AZN:

2.16

PB Ratio

TATYY:

1.54

AZN:

2.63

Total Revenue (TTM)

TATYY:

£3.54B

AZN:

$61.18B

Gross Profit (TTM)

TATYY:

£722.00M

AZN:

$48.56B

EBITDA (TTM)

TATYY:

£597.20M

AZN:

$20.49B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TATYY vs. AZN — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

TATYY
TATYY Risk / Return Rank: 5252
Overall Rank
TATYY Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
TATYY Sortino Ratio Rank: 5454
Sortino Ratio Rank
TATYY Omega Ratio Rank: 5656
Omega Ratio Rank
TATYY Calmar Ratio Rank: 5050
Calmar Ratio Rank
TATYY Martin Ratio Rank: 4848
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 6666
Overall Rank
AZN Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 6666
Sortino Ratio Rank
AZN Omega Ratio Rank: 6262
Omega Ratio Rank
AZN Calmar Ratio Rank: 6565
Calmar Ratio Rank
AZN Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

TATYY vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tate & Lyle PLC ADR (TATYY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TATYYAZNDifference
Sharpe ratioReturn per unit of total volatility

-0.59

Sortino ratioReturn per unit of downside risk

-0.47

Omega ratioGain probability vs. loss probability

1.12

1.15

-0.03

Calmar ratioReturn relative to maximum drawdown

0.19

0.92

-0.73

Martin ratioReturn relative to average drawdown

0.30

2.43

-2.13

TATYY vs. AZN - Sharpe Ratio Comparison

The current TATYY Sharpe Ratio is 0.14, which is lower than the AZN Sharpe Ratio of 0.73. The chart below compares the historical Sharpe Ratios of TATYY and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TATYY vs. AZN - Drawdown Comparison

The maximum TATYY drawdown since its inception was -57.06%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for TATYY and AZN.


Loading charts...

Drawdown Indicators


TATYYAZNDifference

Max Drawdown

Largest peak-to-trough decline

-57.06%

-48.94%

-8.12%

Max Drawdown (1Y)

Largest decline over 1 year

-40.33%

-21.08%

-19.25%

Max Drawdown (3Y)

Largest decline over 3 years

-57.06%

-27.87%

-29.19%

Max Drawdown (5Y)

Largest decline over 5 years

-57.06%

-27.87%

-29.19%

Max Drawdown (10Y)

Largest decline over 10 years

-57.06%

-27.87%

-29.19%

Current Drawdown

Current decline from peak

-26.03%

-18.62%

-7.41%

Average Drawdown

Average peak-to-trough decline

-15.71%

-11.39%

-4.32%

Ulcer Index

Depth and duration of drawdowns from previous peaks

26.03%

7.99%

+18.04%

Volatility

TATYY vs. AZN - Volatility Comparison

The current volatility for Tate & Lyle PLC ADR (TATYY) is 1.97%, while AstraZeneca PLC (AZN) has a volatility of 11.83%. This indicates that TATYY experiences smaller price fluctuations and is considered to be less risky than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TATYYAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

1.97%

11.83%

-9.86%

Volatility (6M)

Calculated over the trailing 6-month period

44.15%

19.94%

+24.21%

Volatility (1Y)

Calculated over the trailing 1-year period

56.28%

27.24%

+29.04%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

37.87%

24.51%

+13.36%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.88%

24.96%

+8.92%

Dividends

TATYY vs. AZN - Dividend Comparison

TATYY's dividend yield for the trailing twelve months is around 3.56%, more than AZN's 3.14% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
3.14%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
TATYY
Tate & Lyle PLC ADR
3.56%5.27%3.03%2.90%19.44%4.72%3.74%3.67%4.18%3.64%3.81%0.00%

Financials

TATYY vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Tate & Lyle PLC ADR and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

TATYY vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Tate & Lyle PLC ADR and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

TATYY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Tate & Lyle PLC ADR reported a gross profit of 0.00 and revenue of 996.75M. Therefore, the gross margin over that period was 0.0%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, AstraZeneca PLC reported a gross profit of 11.18B and revenue of 15.19B. Therefore, the gross margin over that period was 73.6%.

TATYY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Tate & Lyle PLC ADR reported an operating income of 83.23M and revenue of 996.75M, resulting in an operating margin of 8.4%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, AstraZeneca PLC reported an operating income of 3.07B and revenue of 15.19B, resulting in an operating margin of 20.2%.

TATYY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Tate & Lyle PLC ADR reported a net income of 41.62M and revenue of 996.75M, resulting in a net margin of 4.2%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, AstraZeneca PLC reported a net income of 2.48B and revenue of 15.19B, resulting in a net margin of 16.3%.


Frequently Asked Questions


TATYY and AZN have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AZN has higher volatility (11.83%) compared to TATYY (1.97%). In terms of maximum drawdown, TATYY dropped -57.06% vs AZN's -48.94%.

AZN currently has the higher Sharpe Ratio (0.73 vs 0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TATYY and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer